Last updated on August 2018

Study of TSR-033 With an Anti-PD-1


Brief description of study

This is a multicenter, open-label, first-in-human Phase 1 study evaluating TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors in a broad range of solid tumors. Patients with disease types selected for evaluation in this study are expected to derive clinical benefit with addition of an anti-PD-1. The study will be conducted in two parts: dose escalation and cohort expansion.

Detailed Study Description

This is a multi-center, open-label, first-in-human, Phase 1 study evaluating the anti-LAG-3 antibody of TSR-033 alone and in combination with anti-PD-1. The study will be conducted in 2 parts, with Part 1 consisting of dose escalation to determine the RP2D of TSR-033 as a single agent (Part 1a) and in combination with an anti-PD-1 antibody (Part 1c). RP2D decisions will be based on the occurrence of dose-limiting toxicities (DLTs), PK, as well as PDy data. These regimens will be evaluated in patients with advanced solid tumors who have limited available treatment options as determined by the Investigator.

Part 2 of the study will evaluate the anti-tumor activity of TSR-033 in combination with an anti-PD-1 in patients.

Clinical Study Identifier: NCT03250832

Contact Investigators or Research Sites near you

Start Over

Gustave Roussy

Villejuif, France
9.91miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.